Allurion Technologies (NYSE:ALUR) vs. AngioDynamics (NASDAQ:ANGO) Critical Contrast

Allurion Technologies (NYSE:ALUR) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations for Allurion Technologies and AngioDynamics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	0	0	2	0	3.00
AngioDynamics	0	0	4	0	3.00

Allurion Technologies presently has a consensus price target of $5.00, indicating a potential upside of 161.78%. AngioDynamics has a consensus price target of $14.25, indicating a potential upside of 127.64%. Given Allurion Technologies’ higher possible upside, equities research analysts plainly believe Allurion Technologies is more favorable than AngioDynamics.

Institutional & Insider Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 20.0% of Allurion Technologies shares are owned by company insiders. Comparatively, 5.1% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Allurion Technologies has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Profitability

This table compares Allurion Technologies and AngioDynamics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	N/A	N/A	-97.97%
AngioDynamics	-60.21%	-3.48%	-2.68%

Earnings & Valuation

This table compares Allurion Technologies and AngioDynamics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$53.47 million	1.71	-$80.61 million	N/A	N/A
AngioDynamics	$338.75 million	0.74	-$52.44 million	($4.84)	-1.29

AngioDynamics has higher revenue and earnings than Allurion Technologies.

Summary

AngioDynamics beats Allurion Technologies on 6 of the 11 factors compared between the two stocks.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

About AngioDynamics

AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.